Biocompatible Nanovesicular Drug Delivery Systems with Targeting Potential for Autoimmune Diseases

Autoimmune diseases are collectively addressed as chronic conditions initiated by the loss of one’s immunological tolerance, where the body treats its own cells as foreigners or self-antigens. These hay-wired antibodies or immunologically capable cells lead to a variety of disorders like rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, multiple sclerosis and recently included neurodegenerative diseases like Alzheimer’s, Parkinsonism and testicular cancer triggered T-cells induced autoimmune response in testes and brain. Conventional treatments for autoimmune diseases possess several downsides due to unfavourable pharmacokinetic behaviour of drug, reflected by low bioavailability, rapid clearance, offsite toxicity, restricted targeting ability and poor therapeutic outcomes. Novel nanovesicular drug delivery systems including liposomes, niosomes, proniosomes, ethosomes, transferosomes, pharmacosomes, ufasomes and biologically originated exosomes have proved to possess alluring prospects in supporting the combat against autoimmune diseases. These nanovesicles have revitalized available treatment modalities as they are biocompatible, biodegradable, less immunogenic and capable of carrying high drug payloads to deliver both hydrophilic as well as lipophilic drugs to specific sites via passive or active targeting. Due to their unique surface chemistry, they can be decorated with physiological or synthetic ligands to target specific receptors overexpressed in different autoimmune diseases and can even cross the blood-brain barrier. This review presents exhaustive yet concise information on the potential of various nanovesicular systems as drug carriers in improving the overall therapeutic efficiency of the dosage regimen for various autoimmune diseases. The role of endogenous exosomes as biomarkers in the diagnosis and prognosis of autoimmune diseases along with monitoring progress of treatment will also be highlighted.

Download Full-text

Resealed Erythrocytes as Drug Carriers and Its Therapeutic Applications

Pharmaceutical Sciences ◽

10.4018/978-1-5225-1762-7.ch018 ◽

2017 ◽

pp. 459-485

Author(s):

Prabhakar Singh ◽

Sudhakar Singh ◽

Rajesh Kumar Kesharwani

Keyword(s):

Drug Delivery ◽

Blood Cells ◽

Drug Delivery Systems ◽

Release Kinetics ◽

Drug Carrier ◽

Drug Loading ◽

Drug Carriers ◽

Delivery Systems ◽

The Body ◽

Body Ideal

In this pharma innovative world, there are more than 30 drug delivery systems. Today's due to lacking the target specificity, the present scenario about drug delivery is emphasizing towards targeted drug delivery systems. Erythrocytes are the most common type of blood cells travel thousands of miles from wide to narrow pathways to deliver oxygen, drugs and nutrient during their lifetime. Red blood cells have strong and targeted potential carrier capabilities for varieties of drugs. Drug-loaded carrier erythrocytes or resealed erythrocytes are promising for various passive and active targeting. Resealed erythrocyte have advantage over several drug carrier models like biocompatibility, biodegradability without toxic products, inert intracellular environment, entrapping potential for a variety of chemicals, protection of the organism against toxic effects of the drug, able to circulate throughout the body, ideal zero-order drug-release kinetics, no undesired immune response against encapsulated drug etc. Resealed erythrocytes are rapidly taken up by macrophages of the Reticuloendothelial System (RES) of the liver, lung, and spleen of the body and hence drugs also. Resealed erythrocytes method of drugs delivery is secure and effective for drugs targeting specially for a longer period of time. This chapter will explain the different method of drug loading for resealed erythrocytes, their characterization, and applications in various therapies and associated health benefits.

Download Full-text

Resealed Erythrocytes as Drug Carriers and Its Therapeutic Applications

Advances in Medical Technologies and Clinical Practice - Recent Advances in Drug Delivery Technology ◽

10.4018/978-1-5225-0754-3.ch012 ◽

2016 ◽

pp. 340-366

Author(s):

Prabhakar Singh ◽

Sudhakar Singh ◽

Rajesh Kumar Kesharwani

Keyword(s):

Drug Delivery ◽

Blood Cells ◽

Drug Delivery Systems ◽

Release Kinetics ◽

Drug Carrier ◽

Drug Loading ◽

Drug Carriers ◽

Delivery Systems ◽

The Body ◽

Body Ideal

Download Full-text

Niosomes as Nanoparticular Drug Carriers: Fundamentals and Recent Applications

Journal of Nanomaterials ◽

10.1155/2016/7372306 ◽

2016 ◽

Vol 2016 ◽

pp. 1-13 ◽

Cited By ~ 54

Author(s):

Didem Ag Seleci ◽

Muharrem Seleci ◽

Johanna-Gabriela Walter ◽

Frank Stahl ◽

Thomas Scheper

Keyword(s):

Drug Delivery ◽

Drug Delivery Systems ◽

Nonionic Surfactants ◽

Drug Carriers ◽

Delivery Systems ◽

The Body ◽

Scientific Journals ◽

Preparation Methods ◽

Different Types ◽

Self Association

Drug delivery systems are defined as formulations aiming for transportation of a drug to the desired area of action within the body. The basic component of drug delivery systems is an appropriate carrier that protects the drug from rapid degradation or clearance and thereby enhances drug concentration in target tissues. Based on their biodegradable, biocompatible, and nonimmunogenic structure, niosomes are promising drug carriers that are formed by self-association of nonionic surfactants and cholesterol in an aqueous phase. In recent years, numerous research articles have been published in scientific journals reporting the potential of niosomes to serve as a carrier for the delivery of different types of drugs. The present review describes preparation methods, characterization techniques, and recent studies on niosomal drug delivery systems and also gives up to date information regarding recent applications of niosomes in drug delivery.

Download Full-text

Advances in the use of MOFs for Cancer Diagnosis and Treatment: An Overview

Current Pharmaceutical Design ◽

10.2174/1381612826666200406153949 ◽

2020 ◽

Vol 26 (33) ◽

pp. 4174-4184

Author(s):

Marina P. Abuçafy ◽

Bruna L. da Silva ◽

João A. Oshiro-Junior ◽

Eloisa B. Manaia ◽

Bruna G. Chiari-Andréo ◽

...

Keyword(s):

Drug Delivery ◽

Drug Delivery Systems ◽

Rational Design ◽

Gas Adsorption ◽

Drug Loading ◽

Drug Carriers ◽

Delivery Systems ◽

Academic Community ◽

Anticancer Drug Delivery ◽

Diagnostic Agents

Nanoparticles as drug delivery systems and diagnostic agents have gained much attention in recent years, especially for cancer treatment. Nanocarriers improve the therapeutic efficiency and bioavailability of antitumor drugs, besides providing preferential accumulation at the target site. Among different types of nanocarriers for drug delivery assays, metal-organic frameworks (MOFs) have attracted increasing interest in the academic community. MOFs are an emerging class of coordination polymers constructed of metal nodes or clusters and organic linkers that show the capacity to combine a porous structure with high drug loading through distinct kinds of interactions, overcoming the limitations of traditional drug carriers explored up to date. Despite the rational design and synthesis of MOFs, structural aspects and some applications of these materials like gas adsorption have already been comprehensively described in recent years; it is time to demonstrate their potential applications in biomedicine. In this context, MOFs can be used as drug delivery systems and theranostic platforms due to their ability to release drugs and accommodate imaging agents. This review describes the intrinsic characteristics of nanocarriers used in cancer therapy and highlights the latest advances in MOFs as anticancer drug delivery systems and diagnostic agents.

Download Full-text

Nanoscale Drug Delivery Systems for Glaucoma: Experimental and In Silico Advances

Current Topics in Medicinal Chemistry ◽

10.2174/1568026620666200922114210 ◽

2020 ◽

Vol 20 ◽

Author(s):

Smriti Sharma ◽

Vinayak Bhatia

Keyword(s):

Drug Delivery ◽

In Silico ◽

Drug Delivery Systems ◽

Delivery Systems ◽

Ocular Drug Delivery ◽

The Body ◽

Single Wall Carbon Nanotubes ◽

Blood Retinal Barrier ◽

Novel Drugs ◽

Blood Aqueous Barrier

: In this review nanoscale based drug delivery systems particularly in relevance to the antiglaucoma drugs have been discussed. In addition to that, the latest computational/in silico advances in this field are examined in brief. Using nanoscale materials for drug delivery, is an ideal option to target tumours and drug can be released at areas of the body where traditional drugs may fail to act. Nanoparticles, polymeric nanomaterials, single-wall carbon nanotubes (SWCNTs), quantum dots (QDs), liposomes and graphene are the most important nanomaterials used for drug delivery. Ocular drug delivery is one of the most common and difficult tasks faced by pharmaceutical scientists because of many challenges like circumventing the blood–retinal barrier, corneal epithelium and the blood–aqueous barrier. Authors found compelling empirical evidence of scientists relying on in-silico approaches to develop novel drugs and drug delivery systems for treating glaucoma. This review in nanoscale drug delivery systems will help us in understand the existing queries and evidence gaps and will pave way for effective design of novel ocular drug delivery systems

Download Full-text

Nanostructured Ketorolac-Tromethamine/MCF: Synthesis, Characterization and Application in Drug Release System

Current Nanoscience ◽

10.2174/1573413714666180222134742 ◽

2018 ◽

Vol 14 (5) ◽

pp. 432-439 ◽

Cited By ~ 1

Author(s):

Juliana M. Juarez ◽

Jorgelina Cussa ◽

Marcos B. Gomez Costa ◽

Oscar A. Anunziata

Keyword(s):

Drug Delivery ◽

Drug Release ◽

Therapeutic Efficacy ◽

Drug Delivery Systems ◽

Controlled Drug Release ◽

Delivery Systems ◽

The Body ◽

Fickian Diffusion ◽

Ketorolac Tromethamine

Background: Controlled drug delivery systems can maintain the concentration of drugs in the exact sites of the body within the optimum range and below the toxicity threshold, improving therapeutic efficacy and reducing toxicity. Mesostructured Cellular Foam (MCF) material is a new promising host for drug delivery systems due to high biocompatibility, in vivo biodegradability and low toxicity. Methods: Ketorolac-Tromethamine/MCF composite was synthesized. The material synthesis and loading of ketorolac-tromethamine into MCF pores were successful as shown by XRD, FTIR, TGA, TEM and textural analyses. Results: We obtained promising results for controlled drug release using the novel MCF material. The application of these materials in KETO release is innovative, achieving an initial high release rate and then maintaining a constant rate at high times. This allows keeping drug concentration within the range of therapeutic efficacy, being highly applicable for the treatment of diseases that need a rapid response. The release of KETO/MCF was compared with other containers of KETO (KETO/SBA-15) and commercial tablets. Conclusion: The best model to fit experimental data was Ritger-Peppas equation. Other models used in this work could not properly explain the controlled drug release of this material. The predominant release of KETO from MCF was non-Fickian diffusion.

Download Full-text

Polymeric Drug Delivery System Based on Pluronics for Cancer Treatment

Molecules ◽

10.3390/molecules26123610 ◽

2021 ◽

Vol 26 (12) ◽

pp. 3610

Author(s):

Jialin Yu ◽

Huayu Qiu ◽

Shouchun Yin ◽

Hebin Wang ◽

Yang Li

Keyword(s):

Drug Delivery ◽

Self Assembly ◽

Drug Delivery Systems ◽

Tumor Therapy ◽

Chemical Properties ◽

Drug Carriers ◽

Disease Diagnosis ◽

Delivery Systems ◽

Polymeric Drug Delivery ◽

Physical And Chemical

Pluronic polymers (pluronics) are a unique class of synthetic triblock copolymers containing hydrophobic polypropylene oxide (PPO) and hydrophilic polyethylene oxide (PEO) arranged in the PEO-PPO-PEO manner. Due to their excellent biocompatibility and amphiphilic properties, pluronics are an ideal and promising biological material, which is widely used in drug delivery, disease diagnosis, and treatment, among other applications. Through self-assembly or in combination with other materials, pluronics can form nano carriers with different morphologies, representing a kind of multifunctional pharmaceutical excipients. In recent years, the utilization of pluronic-based multi-functional drug carriers in tumor treatment has become widespread, and various responsive drug carriers are designed according to the characteristics of the tumor microenvironment, resulting in major progress in tumor therapy. This review introduces the specific role of pluronic-based polymer drug delivery systems in tumor therapy, focusing on their physical and chemical properties as well as the design aspects of pluronic polymers. Finally, using newer literature reports, this review provides insights into the future potential and challenges posed by different pluronic-based polymer drug delivery systems in tumor therapy.

Download Full-text

Aptamer-modified polymer nanoparticles for targeted drug delivery

BioNanoMaterials ◽

10.1515/bnm-2015-0027 ◽

2016 ◽

Vol 17 (1-2) ◽

Cited By ~ 9

Author(s):

Julia Modrejewski ◽

Johanna-Gabriela Walter ◽

Imme Kretschmer ◽

Evren Kemal ◽

Mark Green ◽

...

Keyword(s):

Lung Cancer ◽

Drug Delivery ◽

Cancer Cells ◽

Targeted Drug Delivery ◽

Drug Delivery Systems ◽

Mode Of Delivery ◽

Delivery Systems ◽

The Body ◽

Lung Cancer Cells ◽

Targeted Drug

AbstractThe purpose of this study was to develop a model system for targeted drug delivery. This system should enable targeted drug release at a certain tissue in the body. In conventional drug delivery systems, drugs are often delivered unspecifically resulting in unwarranted adverse effects. To circumvent this problem, there is an increasing demand for the development of intelligent drug delivery systems allowing a tissue-specific mode of delivery. Within this study, nanoparticles consisting of two biocompatible polymers are used. Because of their small size, nanoparticles are well-suited for effective drug delivery. The small size affects their movement through cell and tissue barriers. Their cellular uptake is easier when compared to larger drug delivery systems. Paclitaxel was encapsulated into the nanoparticles as a model drug, and to achieve specific targeting an aptamer directed against lung cancer cells was coupled to the nanoparticles surface. Nanoparticles were characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM), fourier transform infrared spectroscopy (FTIR), and nanotracking analysis (NTA). Also their surface charge was characterized from ζ-potential measurements. Their preparation was optimized and subsequently specificity of drug-loaded and aptamer-functionalized nanoparticles was investigated using lung cancer cells.

Download Full-text

Alzheimer’s disease and its related Dementia types: A review on their management via nanotechnology based therapeutic strategies

Current Alzheimer Research ◽

10.2174/1567205018666210218160812 ◽

2021 ◽

Vol 18 ◽

Author(s):

Panoraia I. Siafaka ◽

Gökce Mutlu ◽

Neslihan Üstündağ Okur

Keyword(s):

Alzheimer’S Disease ◽

Drug Delivery ◽

Alzheimer's Disease ◽

Vascular Dementia ◽

Drug Delivery Systems ◽

Delivery Systems ◽

The Body ◽

Daily Routine ◽

Mixed Dementia ◽

The Brain

Background: Dementia and its related types such as Alzheimer’s disease, vascular dementia and mixed dementia belong to brain associated diseases, resulting in long-term progressive memory loss. These diseases are so severe that can affect a person's daily routine. Up to date, treatment of de- mentias is still an unmet challenge due to their complex pathophysiology and unavailable efficient pharmacological approaches. The use of nanotechnology based pharmaceutical products could possibly improve the management of dementia given that nanocarriers could more efficiently deliver drugs to the brain. Objective: The objective of this study is to provide the current nanotechnology based drug delivery systems for the treatment of various dementia types. In addition, the current diagnosis biomarkers for the mentioned dementia types along with their available pharmacological treatment are being dis- cussed. Method: An extensive review of the current nanosystems such as brain drug delivery systems against Alzheimer’s disease, vascular dementia and mixed dementia was performed. Moreover, nan- otheranostics as possible imaging markers for such dementias were also reported. Results: The field of nanotechnology is quite advantageous for targeting dementia given that nanoscale drug delivery systems easily penetrate the blood brain barrier and circulate in the body for prolonged time. These nanoformulations consist of polymeric nanoparticles, solid lipid nanoparticles, nanostruc- tured lipid carriers, microemulsions, nanoemulsions, and liquid crystals. The delivery of the nan- otherapeutics can be achieved via various administration routes such as transdermal, injectable, oral, and more importantly, through the intranasal route. Nonetheless, the nanocarriers are mostly limited to Alzheimer’s disease targeting; thus, nanocarriers for other types of dementia should be developed. Conclusion: To conclude, understanding the mechanism of neurodegeneration and reviewing the cur- rent drug delivery systems for Alzheimer’s disease and other dementia types are significant for medical and pharmaceutical society to produce efficient therapeutic choices and novel strategies based on mul- tifunctional and biocompatible nanocarriers, which can deliver the drug sufficiently into the brain.

Download Full-text

Towards feedback-controlled nanomedicines for smart, adaptive delivery

Experimental Biology and Medicine ◽

10.1177/1535370218800456 ◽

2018 ◽

Vol 244 (4) ◽

pp. 283-293 ◽

Cited By ~ 4

Author(s):

Stephen J. Jones ◽

Annette F. Taylor ◽

Paul A Beales

Keyword(s):

Drug Delivery ◽

Drug Release ◽

Drug Delivery Systems ◽

Delivery Systems ◽

The Body ◽

Living Systems ◽

Prolonged Release ◽

Drug Bioavailability ◽

Drug Release Profile ◽

Chemical Systems

Nanomedicines for controlled drug release provide temporal and spatial regulation of drug bioavailability in the body. The timing of drug release is usually engineered either for slow gradual release over an extended period of time or for rapid release triggered by a specific change in its physicochemical environment. However, between these two extremes, there is the desirable possibility of adaptive nanomedicines that dynamically modulate drug release in tune with its changing environment. Adaptation and response through communication with its environment is a fundamental trait of living systems; therefore, the design of biomimetic nanomedicines through the approaches of bottom-up synthetic biology provides a viable route to this goal. This could enable drug delivery systems to optimize release in synchronicity with the body’s natural biological rhythms and the personalized physiological characteristics of the patient, e.g. their metabolic rate. Living systems achieve this responsiveness through feedback-controlled biochemical processes that regulate their functional outputs. Towards this goal of adaptive drug delivery systems, we review the general benefits of nanomedicine formulations, provide existing examples of experimental nanomedicines that encapsulate the metabolic function of enzymes, and give relevant examples of feedback-controlled chemical systems. These are the underpinning concepts that hold promise to be combined to form novel adaptive release systems. Furthermore, we motivate the advantages of adaptive release through chronobiological examples. By providing a brief review of these topics and an assessment of the state of the art, we aim to provide a useful resource to accelerate developments in this field. Impact statement The timing and rate of release of pharmaceuticals from advanced drug delivery systems is an important property that has received considerable attention in the scientific literature. Broadly, these mostly fall into two classes: controlled release with a prolonged release rate or triggered release where the drug is rapidly released in response to an environmental stimulus. This review aims to highlight the potential for developing adaptive release systems that more subtlety modulate the drug release profile through continuous communication with its environment facilitated through feedback control. By reviewing the key elements of this approach in one place (fundamental principles of nanomedicine, enzymatic nanoreactors for medical therapies and feedback-controlled chemical systems) and providing additional motivating case studies in the context of chronobiology, we hope to inspire innovative development of novel “chrononanomedicines.”

Download Full-text